AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Resea...
July 11 2018 - 07:00AM
Business Wire
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE
American: BTX), today announced that Chief Executive Officer
Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will
present at the conference Ending Age-Related Diseases: Investment
Prospects & Advances in Research, Thursday, July 12 at Cooper
Union in New York City.
Scheduled for 2:00pm EDT, Dr. West’s presentation, “Hayflick
Rewound: Somatic Restriction, Epigenetics, and the Reversibility of
Human Aging” will describe AgeX’s induced Tissue Regeneration
(iTRTM) program and its potential clinical application.
Additionally, at 5:05pm Dr. West will participate on a panel,
“Startups in the Aging Sector - Challenges Faced.”
This inaugural one-day event from the Life Extension Advocacy
Foundation will bring together a variety of industry experts to
share insights on advances and investment prospects. Dr. West’s
presentation will be made available on AgeX’s website.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime,
Inc. (NYSE American: BTX), is a biotechnology company focused
on the development of novel therapeutics for age-related
degenerative disease. The company’s mission is to apply the
proprietary technology platform related to telomerase-mediated cell
immortality and regenerative biology to address a broad range of
diseases of aging. The products under development include two
cell-based therapies derived from telomerase-positive pluripotent
stem cells and two product candidates derived from the company’s
proprietary induced Tissue Regeneration (iTR™) technology.
AGEX-BAT1 and AGEX-VASC1 are cell-based therapies in the
preclinical stage of development comprised of young regenerative
cells formulated in the company’s proprietary HyStem® matrix
designed to correct metabolic imbalances in aging and to restore
vascular support in ischemic tissues respectively. AGEX-iTR1547 is
a drug-based formulation in preclinical development intended to
restore regenerative potential in a wide array of aged tissues
afflicted with degenerative disease using the company’s proprietary
iTR technology. Renelon™ is a first-generation iTR product designed
to promote scarless tissue repair which the Company plans to
initially develop as a topically-administered device for commercial
development through a 510(k) application. In addition to the
product candidates in early development, the company, through its
LifeMap subsidiary, currently markets genomic interpretation
algorithms. In addition, the company, through its ESI
BIO division, markets Cytiva®, comprised of PSC-derived heart
muscle cells used in screening drugs for efficacy and safety.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, Facebook and YouTube.
About BioTime
BioTime is a clinical-stage biotechnology company focused
on degenerative diseases. Its clinical programs are based on two
platform technologies: cell replacement and cell/drug delivery.
With its cell replacement platform, BioTime is producing
new cells and tissues with its proprietary pluripotent cell
technologies. These cells and tissues are developed to replace
those that are either rendered dysfunctional or lost due to
degenerative diseases or injuries. BioTime’s cell/drug delivery
programs are based upon its proprietary HyStem® cell and drug
delivery matrix technology. HyStem® was designed, in part, to
provide for the transfer, retention and/or engraftment of cellular
replacement therapies. BioTime’s lead cell delivery clinical
program is Renevia®, which consists of HyStem® combined with
the patient's own adipose (fat) progenitor cells. Renevia® met
its primary endpoint in an EU pivotal clinical trial for the
treatment of facial lipoatrophy in HIV patients in
2017. BioTime has submitted Renevia® for CE Mark
approval in the EU. There were no device related serious adverse
events reported to date. BioTime’s lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium transplant
therapy, which is in a Phase I/IIa multicenter clinical trial for
the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. There were no unexpected
serious adverse events reported to date. BioTime also has
significant equity holdings in two publicly traded
companies, Asterias Biotherapeutics, Inc. (NYSE American:
AST) and OncoCyte Corporation (NYSE American: OCX),
and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company
on Twitter, LinkedIn, Facebook, and
YouTube.
To receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert list:
BioTime Email Alerts.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of BioTime, Inc. and its subsidiaries,
particularly those mentioned in the cautionary statements found in
more detail in the “Risk Factors” section of BioTime’s Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with
the SEC (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation
or intention to update or revise these forward-looking statements
as a result of changed events or circumstances that occur after the
date of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180711005237/en/
Investor Contact for BioTime:David Nakasone,
510-871-4188Dnakasone@biotime.comorMedia Contact for AgeX:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.comorNext Level Agency, Inc.Mark
Leonard, 847-651-9682mark@reachthenextlevel.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2023 to Mar 2024